Testicular cancer represents only 1% of all malignancies occurring in men. However, it is the most frequent malignancy in men between the ages of 20 and 34 years, accounting for 10% to 14% of cancer incidence in that age group. In most instances, the diagnosis of testicular tumors is established with a carefully performed physical examination and scrotal ultrasonography. Tumor markers are useful for determining the presence of residual disease. Cross-sectional imaging studies (CT, MRI) are useful in determining the location of metastases. Chest radiography and CT are used to assess pulmonary disease. Fluorine-18-2-fluoro-2-deoxy-d-glucose (FDG) PET scans have slightly higher sensitivity than CT, but their role in staging testicular cancer has not been determined in a large study. FDG PET may play a role in the follow-up of higher stage seminoma after chemotherapy. Bone scans are useful in the absence of FDG PET scans and should be used when bone metastases are suspected. The ACR Appropriateness Criteria are evidence-based guidelines for specific clinical conditions that are reviewed annually by a multidisciplinary expert panel. The guideline development and revision include an extensive analysis of current medical literature from peer reviewed journals and the application of well-established methodologies (the RAND/UCLA Appropriateness Method and the Grading of Recommendations Assessment, Development, and Evaluation) to rate the appropriateness of imaging and treatment procedures for specific clinical scenarios. In those instances in which evidence is lacking or equivocal, expert opinion may supplement the available evidence to recommend imaging or treatment.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jacr.2016.06.026DOI Listing

Publication Analysis

Top Keywords

fdg pet
12
acr appropriateness
8
appropriateness criteria
8
testicular cancer
8
pet scans
8
specific clinical
8
imaging treatment
8
criteria staging
4
staging of testicular
4
of testicular malignancy
4

Similar Publications

True total-body and extended axial field-of-view (AFOV) PET/CT with 1m or more of body coverage are now commercially available and dramatically increase system sensitivity over conventional AFOV PET/CT. The Siemens Biograph Vision Quadra (Quadra), with an AFOV of 106cm, potentially allows use of significantly lower administered radiopharmaceuticals as well as reduced scan times. The aim of this study was to optimise acquisition protocols for routine clinical imaging with FDG on the Quadra the prioritisation of reduced activity given physical infrastructure constraints in our facility.

View Article and Find Full Text PDF

The radiation exposure to bystanders from nuclear medicine patients is a common concern raised in nuclear medicine departments. The GATE (Geant4 Application for Tomographic Emission) Monte Carlo radiation transport application was used to estimate the dose to a bystander. Two voxelised phantoms were utilised in a GATE Monte Carlo simulation as the radiation source and target.

View Article and Find Full Text PDF

Diagnostic Feasibility of Cardiac PET CT in the Evaluation of Inflammatory, Infectious, and Malignant Heart Disease.

R I Med J (2013)

February 2025

Alpert Medical School of Brown University, Department of Medicine, Division of Cardiology, Rhode Island Hospital.

Cardiac Positron Emission Tomography (PET) is a power- ful imaging tool with diverse applications in the detection and diagnosis of various cardiac conditions, including inflammatory, infectious, and neoplastic processes. Using the radiotracer 18F-fluorodeoxyglucose (18F-FDG), cardiac PET enables the identification of cardiac involvement in diseases such as sarcoidosis and severe infections affecting the heart tissue. Additionally, 18F-FDG PET is valuable in the evaluation of cardiac masses, helping to assess their metabolic activity and potential malignancy.

View Article and Find Full Text PDF

Background: Alzheimer's disease (AD) is a progressive neurodegenerative condition with rising prevalence due to the aging global population. Existing methods for diagnosing AD are struggling to detect the condition in its earliest and most treatable stages. One early indicator of AD is a substantial decrease in the brain's glucose metabolism.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!